NEW YORK (GenomeWeb News) – Austrian biomarker firm Biocrates and Canadian firm Chenomx have signed a co-marketing pact, under which the firms will combine their technologies to generate metabolic profiling tools for monitoring the effects of disease, nutrition, toxins, environment, or drugs on an organism.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.